Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 vs Zoledronic Acid for Bone Metastases
NCT06221072Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of narlumosbart in bone metastasis, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
narlumosbart
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT06221072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221072.